S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
NASDAQ:OPCH

Option Care Health (OPCH) Competitors

$28.56
+0.83 (+2.99%)
(As of 06/2/2023 ET)
Compare
Today's Range
$27.99
$28.72
50-Day Range
$26.84
$32.79
52-Week Range
$24.23
$35.87
Volume
2.85 million shs
Average Volume
3.45 million shs
Market Capitalization
$5.13 billion
P/E Ratio
32.83
Dividend Yield
N/A
Price Target
$37.88

OPCH vs. AMED, CHE, ADUS, AHCO, ENSG, CRSP, CERE, ASND, OGN, and MDGL

Should you be buying Option Care Health stock or one of its competitors? The main competitors of Option Care Health include Amedisys (AMED), Chemed (CHE), Addus HomeCare (ADUS), AdaptHealth (AHCO), The Ensign Group (ENSG), CRISPR Therapeutics (CRSP), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Organon & Co. (OGN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.

Option Care Health vs.

Option Care Health (NASDAQ:OPCH) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.

Amedisys has a net margin of 5.02% compared to Option Care Health's net margin of 3.94%. Amedisys' return on equity of 14.35% beat Option Care Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Option Care Health 3.94% 11.90% 5.19%
Amedisys 5.02% 14.35% 7.89%

97.6% of Option Care Health shares are owned by institutional investors. Comparatively, 96.2% of Amedisys shares are owned by institutional investors. 0.4% of Option Care Health shares are owned by company insiders. Comparatively, 2.1% of Amedisys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Option Care Health had 4 more articles in the media than Amedisys. MarketBeat recorded 8 mentions for Option Care Health and 4 mentions for Amedisys. Option Care Health's average media sentiment score of 0.79 beat Amedisys' score of 0.54 indicating that Option Care Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Option Care Health
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amedisys
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amedisys received 411 more outperform votes than Option Care Health when rated by MarketBeat users. Likewise, 57.58% of users gave Amedisys an outperform vote while only 56.94% of users gave Option Care Health an outperform vote.

CompanyUnderperformOutperform
Option Care HealthOutperform Votes
41
56.94%
Underperform Votes
31
43.06%
AmedisysOutperform Votes
452
57.58%
Underperform Votes
333
42.42%

Option Care Health currently has a consensus target price of $37.88, suggesting a potential upside of 32.62%. Amedisys has a consensus target price of $108.94, suggesting a potential upside of 37.08%. Given Amedisys' higher possible upside, analysts plainly believe Amedisys is more favorable than Option Care Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Option Care Health
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Amedisys
2 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.33

Option Care Health has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Option Care Health$3.94 billion1.30$150.56 million$0.8732.83
Amedisys$2.23 billion1.16$118.61 million$3.4423.10

Option Care Health has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Summary

Option Care Health and Amedisys tied by winning 9 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPCH vs. The Competition

MetricOption Care HealthHome health care services IndustryMedical SectorNASDAQ Exchange
Market Cap$5.13B$2.81B$4.62B$6.27B
Dividend YieldN/A0.28%2.32%6.39%
P/E Ratio32.8337.2282.9412.22
Price / Sales1.301.293,595.9699.65
Price / Cash22.9011.9892.03105.95
Price / Book3.803.195.176.89
Net Income$150.56M-$9.76M$117.97M$193.40M
7 Day Performance2.44%7.23%1.97%2.27%
1 Month Performance-12.90%0.51%2.30%5.07%
1 Year Performance-5.52%-18.08%12.37%1.69%

Option Care Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.8489 of 5 stars
$75.35
-2.5%
$108.94
+44.6%
-31.6%$2.45B$2.22B21.9020,000Analyst Report
CHE
Chemed
2.8051 of 5 stars
$529.60
-2.3%
$610.00
+15.2%
+11.8%$7.95B$2.13B33.3314,167Insider Selling
ADUS
Addus HomeCare
2.769 of 5 stars
$88.37
-0.5%
$112.75
+27.6%
+11.2%$1.43B$951.12M28.5133,182
AHCO
AdaptHealth
3.0593 of 5 stars
$10.42
-0.6%
$18.92
+81.6%
-42.2%$1.40B$3.00B86.8310,900Positive News
ENSG
The Ensign Group
2.5539 of 5 stars
$88.05
-0.6%
$107.80
+22.4%
+14.1%$4.93B$3.03B21.4229,900
CRSP
CRISPR Therapeutics
2.1264 of 5 stars
$64.63
0.0%
$74.89
+15.9%
+6.6%$5.10B$1.20M-9.62473Analyst Report
Insider Selling
Short Interest ↓
Analyst Revision
News Coverage
CERE
Cerevel Therapeutics
1.0432 of 5 stars
$32.54
-2.6%
$34.80
+6.9%
+23.5%$5.10BN/A-12.86200Short Interest ↑
ASND
Ascendis Pharma A/S
2.0948 of 5 stars
$85.78
-4.4%
$146.00
+70.2%
+9.6%$4.92B$53.93M-8.18639Analyst Report
News Coverage
OGN
Organon & Co.
3.165 of 5 stars
$19.27
-1.4%
$29.00
+50.5%
-47.1%$4.92B$6.17B6.6010,000
MDGL
Madrigal Pharmaceuticals
2.2861 of 5 stars
$280.02
-1.7%
$312.36
+11.6%
+282.8%$5.12BN/A-15.4771

Related Companies and Tools

This page (NASDAQ:OPCH) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -